programmed death ligand 1

You have access
Efficacy and Safety of Chemoimmunotherapy in Patients With Advanced Non-small Cell Lung Cancer With Pre-existing Interstitial Pneumonia and Low PD-L1 Expression
AOSA SASADA, HAYATO KAWACHI, TADAAKI YAMADA, TAE HATA, YASUHIRO GOTO, AKIHIKO AMANO, YOSHIKI NEGI, SATOSHI WATANABE, NAOKI FURUYA, TOMOHIRO OBA, TATSUKI IKOMA, AKIRA NAKAO, KEIKO TANIMURA, HIROKAZU TANIGUCHI, AKIHIRO YOSHIMURA, TOMOYA FUKUI, DAIKI MURATA, KYOICHI KAIRA, SHINSUKE SHIOTSU, ASUKA OKADA, YUSUKE CHIHARA, TAKASHI KIJIMA and KOICHI TAKAYAMA

Anticancer Research November 2025, 45 (11) 5045-5057; DOI: https://doi.org/10.21873/anticanres.17845
You have access
Efficacy of Immune Checkpoint Inhibitors in Postoperative Recurrence of Wild-type EGFR Non-Small Cell Lung Cancer
YOSHITO IMAMURA, TAKETO KATO, YUJI NOMATA, SHOJI OKADO, HIROKI WATANABE, YUTA KAWASUMI, KEITA NAKANISHI, YUKA KADOMATSU, HARUSHI UENO, SHOTA NAKAMURA, TETSUYA MIZUNO, TETSUNARI HASE, ICHIDAI TANAKA, MAKOTO ISHII, HIROSHI YATSUYA and TOYOFUMI FENGSHI CHEN-YOSHIKAWA

Anticancer Research August 2024, 44 (8) 3451-3461; DOI: https://doi.org/10.21873/anticanres.17165
You have access
Real-world Efficacy and Safety of Atezolizumab Plus Bevacizumab, Paclitaxel and Carboplatin for First-line Treatment of Japanese Patients With Metastatic Non-squamous Non-small Cell Lung Cancer
NOBUMITSU IKEUCHI, FUMIYASU IGATA, ERIKO KINOSHITA, TOSHIAKI KAWABATA, IBUN TAN, YUSUKE OSAKI, RIKAKO OTSUKA, RINTARO ON, TAKATO IKEDA, AKIRA NAKAO, TOMOYA SASAKI, TAKASHI AOYAMA, RYOSUKE HIRANO, TAISHI HARADA, NORIYUKI EBI, MASAKI FUJITA and HIROYUKI INOUE

Anticancer Research February 2023, 43 (2) 713-724; DOI: https://doi.org/10.21873/anticanres.16210
You have access
Clinicopathological and Prognostic Significance of Programmed Death Ligand 1 Expression in Korean Patients With Triple-negative Breast Carcinoma
HYUN-SOO KIM, SUNG-IM DO, DONG-HOON KIM and SOPHIA APPLE

Anticancer Research March 2020, 40 (3) 1487-1494; DOI: https://doi.org/10.21873/anticanres.14093
You have access
Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung Cancer
SHINKICHI TAKAMORI, KAZUKI TAKADA, KOICHI AZUMA, YUMIKO JOGO, FUMIHIKO KINOSHITA, YUKA KOZUMA, TAICHI MATSUBARA, NAOKI HARATAKE, TAKAKI AKAMINE, GOUJI TOYOKAWA, FUMIHIKO HIRAI, TETSUZO TAGAWA, ISAMU OKAMOTO, YOICHI NAKANISHI, AKIHIKO KAWAHARA, JUN AKIBA, YOSHINAO ODA and YOSHIHIKO MAEHARA

Anticancer Research October 2018, 38 (10) 5903-5907; DOI: https://doi.org/10.21873/anticanres.12934
You have access
Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab
NAOKI HARATAKE, GOUJI TOYOKAWA, TETSUZO TAGAWA, YUKA KOZUMA, TAICHI MATSUBARA, SHINKICHI TAKAMORI, TAKAKI AKAMINE, YUICHI YAMADA, YOSHINAO ODA and YOSHIHIKO MAEHARA

Anticancer Research October 2017, 37 (10) 5713-5717;
You have access
Favorable Disease-free Survival Associated with Programmed Death Ligand 1 Expression in Patients with Surgically Resected Small-cell Lung Cancer
GOUJI TOYOKAWA, KAZUKI TAKADA, NAOKI HARATAKE, SHINKICHI TAKAMORI, TAKAKI AKAMINE, MASAKAZU KATSURA, TAKATOSHI FUJISHITA, FUMIHIRO SHOJI, TATSURO OKAMOTO, YOSHINAO ODA and YOSHIHIKO MAEHARA

Anticancer Research August 2016, 36 (8) 4329-4336;

Main menu

User menu

Search

programmed death ligand 1